Areas of Focus
- Tumor Pharmacology
Work Experience
- 2013-09 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher, Group Leader
- 2011-01 to 2012-06 - Hormel Institute, USA - Postdoctoral Researcher
- 2006-08 to 2013-08 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
- 2004-08 to 2006-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Postdoctoral Researcher
- 1994-08 to 2004-08 - Zhengzhou University - Assistant Lecturer, Lecturer
Academic Background & Achievements
- 2001-09 to 2004-07 PhD: Zhengzhou University
Publications
- A novel strategy for treating oncogene-mutant tumors by targeting tumor microenvironment and synergistically enhancing anti-PD1 immunotherapy, Not mentioned, 2024
- From bench to bedside: current development and emerging trend of KRAS-targeted therapy, Not mentioned, 2024
- A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease, Not mentioned, 2024
- Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphoma, Not mentioned, 2024
- Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma, Not mentioned, 2023
- Design and Synthesis of 1H-Pyrazolo[3,4-d]pyrimidine Derivatives as Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors, Not mentioned, 2023
- Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo, Not mentioned, 2023
- Application of deep generative model for design of Pyrrolo2,3-d pyrimidine derivatives as new selective TANK binding kinase 1 (TBK1) inhibitors, Not mentioned, 2023
- Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors, Not mentioned, 2023
- Design, synthesis and evaluation of (R)-8-((tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as novel selective ACK1 inhibitors to combat acquired resistance to the 3rd-generation EGFR inhibitor, Not mentioned, 2023
- Design, synthesis and biological evaluation of KRASG12C-PROTACs as protein degraders, Not mentioned, 2023
- 18F-Labeled o-aminopyridyl alkynyl radioligands targeting colony-stimulating factor 1 receptor for neuroinflammation imaging, Not mentioned, 2023
- Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against GBM, Not mentioned, 2023
- ASK120067 potently suppresses B-cell or T-cell malignancy in vitro and in vivo by inhibiting BTK and ITK, Not mentioned, 2022
- LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo, Not mentioned, 2022
- Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations, Not mentioned, 2022
- Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants, Not mentioned, 2022
- Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors, Not mentioned, 2022
- Identification of 1H-pyrazolo3,4-bpyridine derivatives as novel and potent TBK1 inhibitors: design, synthesis, biological evaluation, and molecular docking study, Not mentioned, 2022
- ASK120067 (limertinib) Exerts Pre-clinical Anti-tumor Activity by Inhibiting EGFR Exon20 Insertion, Not mentioned, 2022
- Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs, Not mentioned, 2021
- Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors, Not mentioned, 2021
- TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery, Not mentioned, 2021
- Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors, Not mentioned, 2021
- Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2Hpyrimido[4,5-d][1,3]oxazin-1(4H)-ly)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors, Not mentioned, 2020
- Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders, Not mentioned, 2020
- Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88L265P diffuse large B-cell lymphoma, Not mentioned, 2020
- 2-Oxo-3,4-dihydropyrimido4,5-d pyrimidines as new reversible inhibitors of EGFR C797S(Cys797 to Ser797)mutant, Not mentioned, 2020
- Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance, Not mentioned, 2020
- Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation, Not mentioned, 2020
- Design, synthesis and biological study of potent and covalent HER-2 tyrosine kinase inhibitors with low cytotoxicity in vitro, Not mentioned, 2019
- Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR(L858R/T790M/C797S)), Not mentioned, 2019
- Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors, Not mentioned, 2019
- Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S, Not mentioned, 2019
- C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis, Not mentioned, 2019
- DW10075, a novel highly selective inhibitor of vascular endothelial growth factor receptor, exhibits antitumor activities both in vitro and in vivo., Not mentioned, 2016
- Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation, Not mentioned, 2016
- Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation, Not mentioned, 2016
- Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors, Not mentioned, 2016
- Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors (II), Not mentioned, 2016
- A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties., Not mentioned, 2016
- C-5 Substituted Pyrido[2,3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinica resistance-related EGFRT790M mutant, Not mentioned, 2015
- Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I), Not mentioned, 2015
- Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors, Not mentioned, 2015
- 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L858R/T790M), Not mentioned, 2015
- Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors, Not mentioned
Awards
- Shanghai May 1st Labor Medal (2021): City Level
- First Prize for Anti-tumor Class 1 New Drug EGFR Third Generation Inhibitor ASK120067 Project (2021): City Level
